SCHEMBL61680

SCHEMBL61680

COc1nc(Cl)nc(C)c1CN(C)C1CCCc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.42
ALDH1A1 P00352 1/20 0.42
XBP1 P17861 1/20 0.42
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
P4HB P07237 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
RAB9A P51151 1/20 0.36
PFKFB3 Q16875 1/20 0.36
CXCR4 P61073 3/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
GID4 Q8IVV7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL61681 1.00 HTT (0.42) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL61602 0.87 ALDH1A1 (0.46) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL61601 0.87 ALDH1A1 (0.46) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL62244 0.82 C5AR1 (0.42) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL72756 0.82 C5AR1 (0.42) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL61144 0.82 C5AR1 (0.42) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL62258 0.79 GAA (0.36) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL4198970 0.76 KDM4E (0.44) ALDH1A1MEN1KMT2APFKFB3
SCHEMBL1327793 0.76 ALDH1A1 (0.40) HTTALDH1A1XBP1MEN1KMT2A
SCHEMBL1327790 0.76 ALDH1A1 (0.40) HTTALDH1A1XBP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 US disclosed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C3AR1, C5AR1 HTT 4546/4885ALDH1A1 1616/4885XBP1 2768/4885
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C5AR1, C3AR1 HTT 4501/4885ALDH1A1 1684/4885XBP1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.